Company	StageDateRound Size	Total Raised
Engrail Therapeutics	Series BMar 2024$160M	$220M
Co-investors: Stacie Weninger (F-Prime Capital Partners), Peter Bisgaard (Pivotal bioVenture Partners), Jasper Bos (Forbion), Heath Lukatch (Red Tree Venture Capital)
Glycomine	Series BJun 2021$35M	$35M
Co-investors: Jim Trenkle (Sanofi Ventures), Bali Muralidhar (Abingworth)
Reneo Pharmaceuticals	Series BDec 2020$95M Series AMay 2019$50M	$150M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Bali Muralidhar (Abingworth)
Amplyx Pharmaceuticals	Series CMay 2020$53M Series CAug 2017$67M Series BNov 2015$41M	$160M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Alex Kahn (Generation Ventures)
Mirum Pharmaceuticals	Series ANov 2018$120M	$120M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Patrick Heron (Frazier Healthcare Partners), Jonathan Leff (Deerfield Management)
Otonomy	Series DApr 2014$49M Series CSep 2013$46M Series BAug 2010$39M Series BAug 2010$39M	$180M
Co-investors: Chau Khuong (OrbiMed), Brian Dovey (Domain Associates), John McKearn (RiverVest), Jay Lichter (Avalon Ventures), Peter Bisgaard (Pivotal bioVenture Partners), Bill Harrington (Osage University Partners), Heather Preston
Lumena Pharmaceuticals	Series BMar 2014$45M Series AMay 2013$23M	$68M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), John McKearn (RiverVest)
Excaliard Pharmaceuticals	Series ANov 2007$16M	$16M

Niall O’Donnell